China's richest pharma leader steps down as Hengrui chairman by Angus Liu Friday, January 17, 2020 Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune from.
New FibroGen CEO cut post-Lilly 'vacation' for roxadustat by Angus Liu Tuesday, January 14, 2020 New FibroGen CEO and former Eli Lilly vet, Enrique Conterno, cleared some existing investor doubts about roxadustat's potential.
AMAG's move to cut CEO, 2 drugs may not save it: analyst by Kyle Blankenship Thursday, January 9, 2020 AMAG Pharmaceuticals is saying goodbye to its CEO and two drugs after a strategic review, but are the moves too late to save the sinking ship?
Ian Read's latest post-Pfizer gig? Pharma guru at Carlyle Group by Angus Liu Thursday, January 9, 2020 Ian Read is taking on an operating executive job at Carlyle, just as Robert Essner became a senior adviser at the PE firm after retiring from Wyeth.
Longtime Abbott chief Miles White to step down as CEO by Angus Liu Wednesday, November 13, 2019 Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.
Ex-Shire CEO Ornskov emerges as Galderma chief after Nestlé spin by Angus Liu Tuesday, October 8, 2019 Flemming Ornskov, Shire’s most recent CEO and who orchestrated the Baxalta takeover and later the selloff to Takeda, is now Galderma's CEO.
GSK's Walmsley backs gender-gap-focused #MeTooPay campaign by Angus Liu Thursday, October 3, 2019 GSK CEO Emma Walmsley has joined over 100 prominent U.K. businesswomen in a campaign aimed at closing the gender pay gap.
New CEO Paul Hudson's 'clear eyes' on Sanofi see changes ahead by Tracy Staton Tuesday, October 1, 2019 Sanofi CEO Paul Hudson hinted at a coming shakeup—from diabetes to cancer and R&D to marketing. And he's planning to unveil those plans December 10.
Big Pharma CEOs' Chinese names: What they mean by Angus Liu Tuesday, October 1, 2019 Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.
U.S. biopharma CEOs have 'high appetite' for M&A: KPMG by Angus Liu Monday, September 23, 2019 Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.
